News Celta Square and Samsung Medical Center have launched a joint research…
페이지 정보
본문
Signed MOU for Collaboration on Development of AI-Based Contrast Media Adverse Event Prediction Model
Celta Square (CEO Shin Min-kyung), a company specializing in AI/DX-based pharmacovigilance, and Samsung Medical Center's Data Science Research Institute (Director Jeong Myeong-jin) announced on May 23rd that they signed a business agreement for joint research and development of an AI-based CT contrast media adverse event prediction model.
This agreement aims to develop an AI model that predicts adverse events of contrast media administered during CT scans.
The two organizations will collaborate on ▲ research and analysis of data necessary for model development ▲ selection of key factors for the prediction model ▲ development and validation of the adverse event prediction model.
In particular, the combination of Samsung Medical Center's extensive clinical data and medical expertise with Celta Square's next-generation AI/DX-based pharmacovigilance capabilities is expected to generate innovative synergy.
Celta Square, Korea's only AI/DX-based pharmacovigilance company, is developing pharmaceutical safety monitoring and adverse event prediction solutions utilizing big data and AI technologies. In particular, they specialize in building proactive prevention systems by analyzing various adverse drug reactions patterns occurring in real-world medical settings using AI.
The Samsung Medical Center Data Science Institute possesses the largest medical big data collection in Korea and boasts research and development capabilities based on real-world clinical experience and data.
Shin Min-kyung, CEO of Celta Square, stated, "The convergence of pharmacological and medical perspectives is key to accurately predicting and preventing adverse drug reactions." She added, "We expect that the combination of Samsung Medical Center's clinical expertise and Celta Square's AI/DX-based pharmacovigilance technology will expand beyond contrast media adverse reaction prediction models to encompass a variety of drug safety solutions."
Jeong Myeong-jin, Director of the Samsung Medical Center Data Science Institute, stated, "By combining patient data and clinical experience accumulated in the medical field with Celta Square's AI/DX-based pharmacovigilance expertise, we will develop an innovative model that can predict and prevent adverse drug reactions in advance, contributing to safer drug prescribing."
The AI-based contrast agent side effect prediction model to be developed through this agreement is expected to support clinical judgment by medical staff by assessing the risk of side effects for each patient before CT examinations, ultimately contributing to improved patient safety.
